AI Terminal
Valneva SE
Regulatory Filings • Jun 8, 2022
1739_iss_2022-06-08_8d645f06-2f1e-4c07-af4f-daa5b9afb857.pdf
Regulatory Filings
Open in ViewerOpens in native device viewer
VALNEVA SE Campus Bio-Ouest | 6, Rue Alain Bombard 44800 Saint-Herblain, France
Valneva Joins Euronext's Tech Leaders Index
Saint Herblain (France), June 8, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its inclusion in the Euronext Tech Leaders Index which was launched yesterday by Euronext.
The Euronext Tech Leaders Index is composed of 100+ European Tech companies, which were identified by Euronext either to be leaders in their field or to have a particularly strong growth profile. It aims to strengthen the European Tech sector and be a catalyst for the next generation of Tech leaders.
Thomas Lingelbach, Chief Executive Officer of Valneva said, "We would like to thank Euronext for our inclusion in this new Index which will enhance our visibility as an innovative vaccine company. The dedicated services afforded to us through this initiative will a be a great asset moving forward."
The Euronext Tech Leaders' initiative is supported by a powerful network of partners including global investment banks as well as French state-owned investment arm Groupe Caisse des Dépôts.
About the Euronext Tech Leaders Index
Euronext Tech Leaders | euronext.com
About Valneva SE
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.
Media & Investor Contacts
Laëtitia Bachelot-Fontaine VP Global Communications & European Investor Relations M +33 (0)6 4516 7099 [email protected]
Joshua Drumm, Ph.D. VP Global Investor Relations M +001 917 815 4520 [email protected]